Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Cash from Operations (2020 - 2025)

Gain Therapeutics has reported Cash from Operations over the past 6 years, most recently at 4618487.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 4618487.0 for Q4 2025, down 33.69% from a year ago — trailing twelve months through Dec 2025 was 18465432.0 (up 2.16% YoY), and the annual figure for FY2025 was 18465432.0, up 2.16%.
  • Cash from Operations for Q4 2025 was 4618487.0 at Gain Therapeutics, up from 4926436.0 in the prior quarter.
  • Over the last five years, Cash from Operations for GANX hit a ceiling of 2192338.0 in Q3 2021 and a floor of 6076205.0 in Q3 2024.
  • Median Cash from Operations over the past 5 years was 4056540.0 (2021), compared with a mean of 4163147.05.
  • Biggest five-year swings in Cash from Operations: crashed 658.41% in 2021 and later surged 38.97% in 2024.
  • Gain Therapeutics' Cash from Operations stood at 4146365.0 in 2021, then increased by 5.83% to 3904613.0 in 2022, then plummeted by 44.97% to 5660379.0 in 2023, then surged by 38.97% to 3454636.0 in 2024, then plummeted by 33.69% to 4618487.0 in 2025.
  • The last three reported values for Cash from Operations were 4618487.0 (Q4 2025), 4926436.0 (Q3 2025), and 5098982.0 (Q2 2025) per Business Quant data.